Riskpilot← Back to searchSign inGet full accessHoffman Group i Malmö AB
ABActiveOrg 5566910088Husargatan 3Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20051-4 employees
Revenue 2025
SEK 0
EBITDA margin
—
-167% vs 2024
Equity ratio
90.5%
Financial strength
Net profit 2025
SEK 198,6M
+865% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -14M | -167% |
| Net profit | SEK 198,6M | +865% |
| Total assets | SEK 288,7M | +177% |
| Equity | SEK 261,3M | +316% |
| Employees | — | — |
Legal name
Hoffman Group i Malmö AB
Org number
5566910088
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
22 november 2005
Share capital
SEK 100 000
Employees
1-4
VAT registered
No
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall äga och förvalta samt bedriva handel med värdepapper, äga och förvalta fastigheter, bedriva handel med diagnostiska produkter mot industriella och kliniska laboratorier, sjukhus och apotek, bedriva uthyrning av båtar, bedriva tävlingsverksamhet med båtar samt därmed förenlig verksamhet.
Address
Husargatan 3
Email
fredrik.alexandersson@hoffman-group.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 4 320 | 5 241 | 6 791 | 10 546 | 13 469 | 17 398 | 23 317 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 8 999 | 3 521 | 3 322 | 2 407 | 1 189 | 9 624 | 11 145 | 16 045 | 20 713 | −13 973 |
| Depreciation & amort. | −634 | −0 | −0 | −1 028 | −1 028 | −0 | −0 | −0 | −11 | −411 |
| EBIT | 8 365 | 3 521 | 3 322 | 1 379 | 161 | 9 624 | 11 145 | 16 045 | 20 702 | −14 384 |
| Net financials | 7 455 | 4 036 | 321 | 1 605 | 267 | 843 | 732 | −84 | −2 922 | 198 299 |
| Profit before tax | 13 721 | 6 966 | 2 946 | 10 440 | 4 413 | 16 128 | 17 124 | 18 988 | 26 700 | 198 643 |
| Tax | −1 385 | −654 | −669 | −1 564 | −957 | −3 461 | −3 604 | −3 984 | −6 113 | −0 |
| Net profit | 12 336 | 6 312 | 2 277 | 8 876 | 3 456 | 12 667 | 13 520 | 15 004 | 20 587 | 198 643 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 24 446 | 23 188 | 24 752 | 29 241 | 30 544 | 44 507 | 60 173 | 72 727 | 104 179 | 288 731 |
| Equity | 18 210 | 16 022 | 14 299 | 20 575 | 19 031 | 28 099 | 34 618 | 46 572 | 62 809 | 261 252 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 634 | 1 974 | 4 564 | 988 | 2 919 | 3 077 | 8 571 | 3 721 | 10 070 | 3 879 |
| Total debt | 1 634 | 1 974 | 4 564 | 988 | 2 919 | 3 077 | 8 571 | 3 721 | 10 070 | 3 879 |
EBITDA margin
-1397300000.0%
This company
15.8%
Market median
-8843670986% vs market
20162025
Equity ratio
90.5%
This company
38.2%
Market median
+137% vs market
20162025
Return on equity
76.0%
This company
18.4%
Market median
+313% vs market
20162025
Net profit margin
19864300000.0%
This company
8.1%
Market median
+245238271505% vs market
20162025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162025
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-05-01 – 2016-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
FO Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
PL Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hoffman Group i Malmö AB 
Miclev Medical Products ABBoard members of Hoffman Group i Malmö AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fredrik Oskar Erik Alexandersson | Chief Executive Officer | 0 companies |
| Per Lenny Persson | Audit | 0 companies |
| Johan Otto Per Wallin | Deputy Board Member | 0 companies |